Vera Therapeutics

News

Otsuka's Voyxact faces rival as FDA okays Vera IgAN drug

Vera Therapeutics has won FDA approval for Trutakna, a BAFF/APRIL inhibitor for IgAN that will compete with Otsuka's recently-launched Voyxact.

News

Vertex chief executive Reshma Kewalramani

Vertex preps FDA filing for IgAN drug after phase 3 readout

Vertex's bid to expand beyond cystic fibrosis has taken a big step forward with phase 3 data for povetacicept in severe kidney disorder IgAN.

News

Otsuka joins IgAN market with Voyxact approval in US

Otsuka has claimed FDA approval for its IgAN therapy Voyxact, joining an increasingly crowded market and beating rival Vera Therapeutics to the punch.

News

Otsuka, Vera stake their claims to IgAN treatment

Otsuka and Vera both have new phase 3 data on drugs for kidney disease IgA nephropathy, but can they make a mark in an increasingly crowded market?

News

Vera prices $250m offer, and other biotech financings

Our round-up of recent biotech financings is headed by a $250 million public offering for late clinical-stage biotech Vera Therapeutics, with an initial public offering (I

Otsuka's Voyxact faces rival as FDA okays Vera IgAN drug

Vertex preps FDA filing for IgAN drug after phase 3 readout

Otsuka joins IgAN market with Voyxact approval in US

Otsuka, Vera stake their claims to IgAN treatment

Vera prices $250m offer, and other biotech financings

Lundbeck preps for key bexicaserin data around year-end

Discover a new era of healthcare panel engagement: Grounded ...

Vera Therapeutics

Editor's Picks